USA flag logo/image

An Official Website of the United States Government

Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44AI096613
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
VENATORX PHARMACEUTICALS, INC.
30 Spring Mill Drive Malvern, PA 19355
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND
Agency: HHS
Contract: 2R44AI096613-03A1
Award Amount: $3,000,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. While carbapenems are among the most prescribed antibiotics for infections caused by these organisms, carbapenem resistance conferred by zinc-based metallo-carbapenemases (Amber Class B) is a growing global health concern that threatens to erode the efficacy of these antibiotics both in the hospital and community settings. Members of this family of resistance enzymes such as NDM-1 are found on promiscuous plasmids with other MDR resistance mechanisms, and are rapidly spreading throughout Enterobacteriaceae. The concern now is that, in the absence of clinically available MBL inhibitors (i.e. MBLs are refractory to clinically available legacy inhibitors tazobactam, clavulanic acid and sulbactam), MBLs such as NDM-1 could become the dominant carbapenemases in clinical settings. As there are currently no MBL inhibitors in pharmaceutical development, there is an urgent need to progress compounds into the drug development pipeline to address this growing issue and safeguard carbapenems. In the Phase I work, we identified a pre-development candidate, VNRX-5113, meeting or exceeding established success criteria including potent and selective inhibitoryactivity against NDM-1 and VIM MBLs, rescue of Meropenem activity in recent and representative NDM/VIM-producing clinical isolates of Enterobacteriaceae, P. aeruginosa and A. baumannii, established in vivo efficacy in a murine septicemia model and preliminary pharmacokinetics compatible with t.i.d. dosing with Meropenem. We also identified 4 potential backup compounds to VNRX-5113 as contingencies. The Phase II application endeavors to drive this first in class MBL inhibitor candidate (VNRX-5113) throughIND-enabling studies to an Investigational New Drug filing. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Metallo-?-lactamase enzymes such as NDM-1 and VIM-variants are spreading throughout Enterobacteriaceae and pose a serious threat to ?-lactam efficacy in both the hospital and community settings. The increased use of generic carbapenems will impose further selective pressure for these enzymes. As there are currently no available inhibitors for Metallo ? -lactamases (MBLs), nor any prospectsin pharmaceutical development, the future utility of carbapenems is uncertain. To address this medical need, we have selected a pre-development candidate MBL inhibitor (VNRX-5113) with potent inhibitory activity against NDM-1 and VIM-variants, capable ofrescuing meropenem activity in NDM/VIM-producing clinical isolates of Enterobacteriaceae and select non- fermenters (Pseudomonas aeruginosa and Acinetobacter baumannii). We believe that VNRX-5113 will fill the gap in ?-lactamase coverage and safeguard thefuture utility of carbapenems.

Principal Investigator:

Luigi Xerri
484-595-6990
xerri@venatorx.com

Business Contact:

Luigi Xerri
610-644-8935
xerri@venatorx.com
Small Business Information at Submission:

VENATORX PHARMACEUTICALS, INC.
30 Spring Mill Drive Malvern, PA 19355

EIN/Tax ID: 127278219
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No